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ABSTRACT
Bisulfite amplicon sequencing has become the pri-
mary choice for single-base methylation quantifica-
tion of multiple targets in parallel. The main limitation
of this technology is a preferential amplification of an
allele and strand in the PCR due to methylation state.
This effect, known as ‘PCR bias’, causes inaccurate
estimation of the methylation levels and calibration
methods based on standard controls have been pro-
posed to correct for it. Here, we present a Bayesian
calibration tool, MethylCal, which can analyse jointly
all CpGs within a CpG island (CGI) or a Differentially
Methylated Region (DMR), avoiding ‘one-at-a-time’
CpG calibration. This enables more precise model-
ing of the methylation levels observed in the stan-
dard controls. It also provides accurate predictions
of the methylation levels not considered in the con-
trolled experiment, a feature that is paramount in the
derivation of the corrected methylation degree. We
tested the proposed method on eight independent
assays (two CpG islands and six imprinting DMRs)
and demonstrated its benefits, including the ability
to detect outliers. We also evaluated MethylCal’s cal-
ibration in two practical cases, a clinical diagnostic
test on 18 patients potentially affected by Beckwith–
Wiedemann syndrome, and 17 individuals with celiac
disease. The calibration of the methylation levels ob-
tained by MethylCal allows a clearer identification of
patients undergoing loss or gain of methylation in
borderline cases and could influence further clinical
or treatment decisions.
INTRODUCTION
DNA methylation is an epigenetic mark associated with a
broad range of disorders including cancer (1), autoimmu-
nity (2), aging (3) and imprinting (4). This mechanism im-
plies the addition of a methyl group to the 5′-carbon of cy-
tosine in a CpG dinucleotide to form 5-methylcytosine (5-
mC) (5). Modifications in DNA methylation could affect
gene expression as reported in several types of diseases (6–
9).
To validate epigenome associations, identify region of in-
terest or clinically relevant biomarkers and create new di-
agnostic tests, it is crucial to develop fast, cheap and ac-
curate DNA methylation assays (10) In this sense, bisulfite
amplicon sequencing is an ideal choice for its capacity to
analyse multiple targets in parallel with high accuracy, con-
cordance and low cost (11). However, this method critically
requires the amplification of bisulfite converted DNA for
the discrimination between un-methylated and methylated
cytosines. The bisulfite conversion consists in the modifica-
tion of un-methylated cytosines on uracil (U) maintaining
methylated cytosines as cytosines (C). The result of the con-
version is a single strand fragmented DNA no longer com-
plemented. If there is a preferential amplification of an allele
and strand in the PCR, this effect is called ‘PCR bias’ (12).
In order to obtain accurate results, it is important to min-
imize its effect as much as possible. To this end, investiga-
tors (13,14) have proposed to redesign primers by looking at
strand-specific as well as bisulfite-specific flanking primers,
but this solution is expensive and time consuming and might
not solve the problem completely. Instead, PCR bias can
be calculated and corrected in silico (12,15) by using stan-
dard controls with known methylation levels. Specifically,
the best-fit hyperbolic (12) and cubic polynomial (15) curve
obtained from the apparent level of methylation after PCR
in standard controls is used to correct the observed methy-
lation levels in the case and control samples.
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In this work, we propose a new Bayesian calibration
method that overcomes the limitations of the existing tools.
In particular, our method analyses jointly all CpGs within a
CGI or a DMR, avoiding ‘one-at-a-time’ CpG calibration
or the calibration of the average methylation level across
CpGs that neglects the variability across CpGs (15,16). To
test the proposed method, we designed eight independent
assays in two CGIs located on SDHC gene promoter and
six imprinted DMRs, see Table 1 for details. After genomic
DNA bisulfite conversion, each target region was ampli-
fied by specific primers, and specific amplicons were se-
quenced on MiSeq. Each assay was run on five standard
controls with known methylation percentages (0%, 25%,
50%, 75% and 100%) to determine the specific calibration
curve through MethylCal. Compared to existing calibration
tools (12,15), our method is able to capture with precision
the variability of the apparent level of methylation observed
after amplification at different actual methylation percent-
ages. We demonstrate this feature and the benefits of our
method when deriving the calibration curves in all the as-
says analysed.
When applied to a data set consisting of 18 patients
potentially affected by Beckwith–Wiedemann syndrome
(BWS) (17), the calibration curves obtained by our new
method permit a more precise correction of the observed
levels of methylation in two target regions (KCNQ1OT1 and
H19/IGF2) with a clearer identification of patients under-
going loss or gain of methylation. We also validated Methyl-
Cal in a second data set regarding patients with celiac dis-
ease (16,18). Our method achieved better calibrations and
more reliable corrections of the methylation levels in three
target regions that have been associated with susceptibil-
ity to celiac disease. These features are important in clini-
cal practice, since the accurate calibration of the methyla-
tion levels obtained by more sophisticated statistical meth-
ods could influence treatment decisions or further actions.
MATERIALS AND METHODS
Samples
For standard controls, we used Human methylated and
non-methylated DNA set from Zymo (Zymo, CA, USA).
The non-methylated DNA was purified from HCT116
DKO cells knockout for both DNA methyltransferases
DNMT1 (–/–) and DNMT3b (–/–). The methylated DNA
was purified from the same HCT116 DKO cells and
was enzymatically methylated by M.SssI methyltransferase.
Five actual methylation percentage (0%, 25%, 50%, 75%
and 100%) were prepared mixing different ratios of non-
methylated and methylated human control DNA (Zymo,
CA, USA) bisulphite converted (MethylEdge Bisulfite Con-
version System, Promega). Additionally, we collected DNA
from 18 potential BWS patients and 15 healthy controls.
Genomic DNA was extracted from peripheral blood using
Gentra Puregene Blood Kit (Qiagen) and DNA quality was
determined by Qubit 2.0 (Invitrogen, ThermoFisher). Ap-
propriate human subject approvals and written inform con-
sent were obtained from all participants. Bisulphite conver-
sion of genomic DNA was performed in all samples at the
same time with MethylEdge Bisulfite Conversion System
from Promega.
PCR amplification
We designed eight assays to quantify the methylation level
at each CpG site in two CGIs located on SDHC gene pro-
moter and six imprinted DMRs, see Table 1 for details.
For the design of the primers we used Bisulfite Primer
Seeker 12S a tool developed by Zymo (http://bpsbackup.
zymoresearch.com/). The primers parameters were: 20–
32 bp primer length, 150–220 bp product length, 55–57◦C
Tm, allowing 1 CpG in the first 1/3 of primer, whereas
the minimum number of CpGs per product is 4. All de-
signs were tested for primer dimers by the Multiple Primer
Analyzer software (ThermoFisher). To allow sequenc-
ing through Nextera XT kit (Illumina), we added over-
hangs sequences to each primer, forward overhang 5′-T
CGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3′ and re-
verse overhang 5′-GTCTCGTGGGCTCGGAGATGTGTATAA
GAGACAG-3′. All standard controls were bisulfite con-
verted at the same time and eight specific PCRs were run
at the same time using the same standard controls. To de-
termine the conversion rate, we examined the conversion of
cytosines on thymidine in non-CpG sites in non-methylated
control DNA (0%) showing a conversion rate higher than
98% (19,20). The sequences of the PCR primers used are
listed in Table 1. The PCR reactions were carried out in
25 l with ZymoTaq Premix (Zymo) using 1.2 l of bisul-
phite converted DNA. The amplification program was 95◦C
for 10 min, then 40 cycles at 95◦C for 30 s, 58◦C for 40 s
and 72◦C for 1 min, and elongation step at 72◦C for 7 min.
PCR products were purified with QIAquick PCR Purifica-
tion Kit (Qiagen). To attached dual indices and Illumina se-
quencing adapters we performed a second PCR of the pu-
rified products using Nextera XT index kit (Illumina) fol-
lowing the recommendations of manufacturer’s. The second
PCR was purified with AMPure XP beads (Beckman Coul-
ter), quantified by Qubit 2.0 (Invitrogen) and normalized to
4 nM.
Bisulphite sequencing
Fastq files obtained by MiSeq system (Illumina) were
trimmed with cutadapt software (http://cutadapt.
readthedocs.io/en/stable/) using quality (-q 30) and
short reads (-m 50) parameters. Trimmed reads were
aligned with bismark software using human reference
build hg19 (https://www.bioinformatics.babraham.ac.
uk/projects/bismark/). Finally, to extract the methyla-
tion level per every single cytosine, we used the tool
bismark methylation extractor included in the bismark
package.
MethylCal
Model outline. MethylCal is a fully Bayesian mixed ad-
ditive regression model. It predicts the apparent level of
methylation observed after amplification based on the ac-
tual methylation percentages (AMP), borrowing informa-
tion across all CpGs within a CGI or a DMR. MethylCal’s
regression model can be described as follows
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Table 1. Sequences of the PCR primers used in this study (TSS for transcription start site, IG for intergenic, and alt-TSS for alternative transcription start
site)
CGI/DMR Position (hg19) Amplicon No. of Primer name Primer sequences
symbol length, bp CpGs
SDHC CpG:17 chr1:161283846-161284062 217 11 SDHC17 F 5′-TGYGAAGTTTTTAAGGAAGAATTTAAATAAG-3′
SDHC17 R 5′-RCTCAACTCTACCTAACTAATTTAC-3′
SDHC CpG:27 chr1:161284062-161284311 250 16 SDHC27 F 5′-GYGGAGAAGTTTTAGAGTTTTTTAAAGAG-3′
SDHC27 R 5′-AAACACAAAATAAACAATTATCAACAAAAC-3′
PLAGL1:alt-TSS-DMR chr6:144329490-144329722 232 28 PLAGL1 F 5′-GYGGTAGTTAAGAGGATGGTTG-3′
PLAGL1 R 5′-CCTAAACRACCTTAACTTTACCCC-3′
GRB10:alt-TSS-DMR chr7:50849242-50849440 198 8 GRB10 F 5′-AGATATTTAYGTTTTTTTTTATTGGGTTAGG-3′
GRB10 R 5′-AACAATCRAATCACCTATTCCAC-3′
MEST:alt-TSS-DMR chr7:130131671-130131913 242 5 MEST F 5′-ATTAGGGGAGGGTTTTTGTAGTAG-3′
MEST R 5′-ACCRCCATAACCACAAAAATAAAATAC-3′
H19/IGF2:IG-DMR chr11:2019495-2019709 214 12 H19 F 5′-GATTTTAYGTTTTTGGAGAGTAGGG-3′
H19 R 5′-AACATACRATCTTCAAACAAAAAAATAACC-3′
KCNQ1OT1:TSS-DMR chr11:2721402-2721616 214 17 KvDMR1 F 5′-ATGTTATTYGGGTTTAGATTGGTTTAG-3′
KvDMR1 R 5′-CACCCCRAAATAATAAACACATCAC-3′
MEG3:TSS-DMR chr14:101293752-101293975 223 11 MEG3 F 5′-TYGTTTATTTAAGAGGGAATAGTTTTGAG-3′
MEG3 R 5′-ACRATAACCCCTCACTAACCTTATC-3′
For easy of notation, in the main text, tables and figures’ caption, and supplementary material, we refer only to the gene name instead of the CGI/DMR symbol.
where yij ∈ [0%, 100%] is the apparent level of methylation
after PCR at the ith AMP (i = 1, . . . , l) and the jth CpG (j
= 1, . . . , m), xij is the ith AMP (x1j = 0% and xlj = 100%)
which is constant across CpGs (in our experimental design
0%, 25%, 50%, 75% and 100% actual methylation are the
same for all CpGs) and 0, . . . , 3 are the coefficients of the
polynomial regression. Finally, εi j ∼ N(0, σ 2).
MethylCal is based on Moskalev’s cubic polynomial re-
gression (CPR) (15) given its simplicity, flexibility and ef-
fectiveness to calibrate methylation data. However, instead
of fitting a distinct CPR for each CpG, in (1) CpGs are
jointly analysed using all n = l × m observations at once.
The second key feature of our model is the inclusion of the
random-effects REij (i = 1, . . . , l, j = 1, . . . , m) that capture
distinct effects at each AMP or CpG or a combination of
both. Depending on how REij is defined, different models
can be derived from (1). In the next section, we present the
specification of REij that we found useful in order to model
accurately the apparent level of methylation after PCR in
standard controls.
Random-effects specification. MethylCal includes four re-
gression models that differ by the specification of the
random-effects REij and the model that fits better the data is
selected by the Deviance Information Criterion (DIC) (21).
The regression models considered in MethylCal are
M1 : yi j = β0 + β1xi j + β2x2i j + β3x3i j
+AMPi + εi j , (2)
M2 : yi j = β0 + β1xi j + β2x2i j + β3x3i j
+AMPi + CpG j + εi j , (3)
M3 : yi j = β0 + β1xi j + β2x2i j + β3x3i j
+AMPi + μ j + εi j , (4)
M4 : yi j = β0 + β1xi j + β2x2i j + β3x3i j
+AMPi + CpG j + CpG∗j xi j + εi j , (5)
Besides the fixed-effects polynomial regression terms, in
(2) the random-effects AMPi are introduced to model the
variability of the apparent level of methylation after PCR at
different AMPs not explained by the CPR. In (3) the crossed
random-effects (22) CpGj are added to capture the hetero-
geneity of the apparent level of methylation across CpGs. In
(4) the latent Gaussian field (LGF) μ = (μ, . . . , μm)T (23)
replaces the crossed random-effects CpGj to model the de-
pendence of the apparent levels of methylation across CpGs.
Finally, in (5) the random-slopes (22) CpG∗j are added to
model the larger (smaller) variability of the apparent level
of methylation after PCR across CpGs at lower (higher)
AMPs. The opposite scenario with a smaller (larger) vari-
ability at lower (higher) AMPs is also considered in (5). For





jCpGj = 0 and
∑
jCpG∗j = 0.
Supplementary Figure S.1 provides a schematic represen-
tation of MethylCal’s regression models, highlighting the
role of the CPR, the crossed random-effects AMPi and
CpGj, the LGF μ and the combined effect of the random-
intercepts CpG and random-slopes CpG∗ in predicting the
apparent level of methylation after PCR.
Priors set-up. Since MethylCal is a fully Bayesian model,
a prior distribution is specified for each unknown pa-
rameter. The fixed-effects regression coefficients follow a
non-informative normal prior distribution, β1, . . . , β4 ∼
N(0, 103), whereas for the intercept an improper prior dis-
tribution is used, π (β0) ∝ β−10 . The crossed random-effects
AMPi and CpGj follow a normal distribution, AMPi |τ ∼
N(0, τ−1) and CpG j |υ ∼ N(0, υ−1) with a non-informative
prior precision τ ∼ Gam(1, 0.1) (E(τ ) = 10 and Var(τ ) =
100) and υ ∼ Gam(1, 0.1). For the LGF, we follow (24)
and model μ as a Random Walk of order 1 (RW1) (25),
μ j |μ j−1, ρ j ∼ N(μ j−1, ρ j ), where  j =  |pj − pj − 1| with
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tion of two consecutive CpGs (with p0 = 0). With this speci-
fication the dependence between methylation levels depends
on the distance between the corresponding CpGs, i.e., the
closer the CpGs, the stronger the dependence. Finally, for
the random-intercepts/slopes model, we specify a Normal-
Wishart prior, (CpGj,CpG∗j )|	 ∼ N2(0, 	−1), with 	 ∼
W2(r, R) (E(	−1) = R/(r − 3)). The default values for the
Wishart hyperparameters are r = 4 and R = I2. The prior
set-up is completed by the specification of a proper but
relatively uninformative prior on the error variance, σ 2 ∼
InvGam(10−10, 0.001).
Advantages of the proposed model. MethylCal has several
advantages compared to existing calibration tools. First,
CpGs are jointly analysed using all n = l × m observa-
tions at once, avoiding unrealistic assumptions of indepen-
dence of the methylation levels at nearby CpGs. Second,
MethylCal is more parsimonious with fewer parameters
to estimate (five for the main effects, including the error
variance, and l + 1, l + m + 2, and l + 2m + 4 random-
effects coefficients for model M1, M2-M3 and M4, respec-
tively, in contrast to 5m coefficients required by Moskalev’s
CPR, where m is the number of CpGs in a DMR or CGI).
Combined with a larger sample size, it allows narrower
coefficients credible intervals and smaller prediction cred-
ible intervals, i.e., less model uncertainty. Third, differently
from a simple fixed-effects model, the specification of dif-
ferent random effects allows MethylCal to adequately ac-
count for the patterns of variances and correlations of the
methylation levels. While in Moskalev’s method Var(Yi j ) =
σ 2j is constant across AMPs, MethylCal allows a more
complex variance structure. In model M1, Var(Yi j |σ 2, τ ) =
σ 2 + τ−1, where −1 models the variability of the appar-
ent level of methylation after PCR across AMPs. In model
M2, Var(Yi j |σ 2, τ, υ) = σ 2 + τ−1 + υ−1 with  −1 the addi-
tional variability of the apparent level of methylation across
CpGs, whereas in model M3, the RW1 induces the autore-
gressive variance decomposition Var(Yi j |σ 2, τ, ρ) = σ 2 +
τ−1 + ρ ∑ jh=1 |ph − ph−1|. In model M4, Var(Yi j |σ 2, 	) =
σ 2 + τ−1 + 	−111 + x2i j	−122 + 2xi j	−112 with 	−111 , 	−122 and
	−112 the elements of the covariance matrix 	
−1. Finally, in
contrast to Moskalev’ CPR, MethylCal is able to capture
the dependence between the observations and, in particular,
the dependence of the methylation levels across CpGs (26).
For instance in model M4, Cov(Yi j , Yi ′ j ′ |σ 2, 	) = τ−1 +
	−111 + xi j xi ′ j ′	−122 + (xi j + xi ′ j ′ )	−112 with Yij and Yi ′ j ′ the
observations from two distinct AMPs and CpGs and with
xij and xi ′ j ′ the corresponding actual methylation percent-
ages.
Inference. Inference on MethylCal’s parameters is per-
formed using INLA R package (http://www.r-inla.org/).
INLA is a probabilistic language that performs approx-
imate Bayesian inference by means of integrated nested
Laplace approximations (27) and numerical integrations.
The main advantage of INLA is its simplicity since a known
practical impediment of Monte Carlo Markov chain meth-
ods in real applications is the large computational burden.
Instead, INLA only requires the specification of the re-
gression model, similarly to other regression packages in
R (https://www.r-project.org/). A second advantage is its
computational speed since no sampling is required from the
posterior densities. This is particularly important in model
M3 since LGF posterior inference is rather difficult using
Monte Carlo Markov chain.
Let β = (β0, β1, β2, β3), γ = (σ 2, τ, υ,	) and μ be the
vector of the fixed effects, the vector of variance com-
ponents and the LGF, respectively. Integrating out the
random-effects AMPi, CpGj and CpG∗j , (2)–(5) can be
rewritten in a more compact formulation that encompasses
all models considered
yi j |β, γ ,μ ∼ π (yi j |β, γ ,μ), (6)
μ|ρ ∼ N(μ(ρ), Q−1(ρ)), (7)
β ∼ π (β), γ ∼ π (γ ), ρ ∼ π (ρ), (8)
where (6) is the observations equation, (7) is the latent Gaus-
sian field equation with mean μ(ρ) and sparse precision ma-
trix Q(ρ) and (8) are the parameters equations. INLA infer-
ential procedure for MethylCal’s models consists of three
steps:
(1) Compute the approximation to the marginal poste-
rior π (β, γ , ρ|y) and by-product to π (β|y), π (γ |y) and
π (ρ|y);
(2) Compute the approximation to π (μ j |y, ρ);
(3) Combine 1. and 2. above to compute π̂ (μ j |y) =∫
π̂ (μ j |y, ρ)π̂ (ρ|y)dρ, where π̂ (·) is the approximated
density.
Note that steps 2 and 3 are only required for model M3.
Despite the Laplace approximations and numerical integra-
tions, INLA provides results that are very close to those ob-
tained by exact MCMC methods. Details about INLA pro-
cedure can be found in (28) and (23).
Given the additive structure of MethylCal, the predictive
values are derived straightforwardly. For example, in model
M3, E(Yi j |xi j ) = E(β|y)xi j + E(AMPi |y) + E(μ j |y),
E(Yi j |xi j ) ∈ [0%, 100%], with xi j = (1, x1i j , x2i j , x3i j )T, E(β|y)
the posterior mean of the fixed effects, E(AMPi |y) the pos-
terior mean of the random-effects AMP at the ith level and
E(μ j |y) the posterior mean of the LGF at the jth CpG. Sim-
ilarly, qα(Yi j |xi j ) = qα(β|y)xi j + qα(AMPi |y) + qα(μ j |y),
where q( · ) ∈ [0%, 100%] is the % quantile of the
posterior distribution.
Predictive measures
We compare the predictive ability of the MethylCal’s model
selected by the DIC with Moskalev’s CPR. In particular, we
report the following ‘in-sample’ and ‘out-of-sample’ predic-
tive measures:
• Residual Sum of Squares: RSS = ∑i j {yi j − E(Yi j |x)}2;
• Mean Squared Error of Prediction (29): MSEP =∑
i j {yi j − E(Yi j |x\(i j ))}2/n, where E(Yi j |x\(i j )) indicates
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to the ith AMP and jth CpG is excluded from the regres-
sion. We also consider the case E(Yi j |xi\ j ) when the jth
CpG is removed and E(Yi j |x\i, j ) when the ith AMP is ex-
cluded from all CpGs;
• CV-index (30): CV = 1 − MSEP/∑i j (yi j − ȳi\ j )2/n,
where ȳi\ j = 1/(m − 1)
∑
i, j ′ 	= j yi j ′ is the average ap-
parent level of methylation after PCR without the
measurement corresponding to the jth CpG. MSEP is
the Mean Squared Error of Prediction when x\(i j ) or xi\ j
are removed from the regression. The case x\i, j is not
considered.
The RSS ∈ [0, 1] is a measure of ‘in-sample’ fit and it is
well known that over-parameterized models achieve usu-
ally better RSS. The MSEP ∈ [0, +∞) is instead a mea-
sure of ‘out-of-sample’ prediction based on leave-one-out
cross-validation. A model with lower MSEP should be pre-
ferred since it predicts more accurately the apparent level
of methylation after PCR for unobserved values of the ac-
tual methylation percentages, a feature that is important in
the derivation of the corrected methylation degree. Finally,
the CV-index ∈ ( − ∞, 1] is similar to MSEP, but it aims at
comparing the ‘out-of-sample’ prediction of the proposed
model with a simpler non-parametric model that predicts
the apparent level of methylation after PCR by using the av-
erage value of all other observations. A negative CV-index is
in favour of a simpler non-parametric model versus a more
sophisticated parametric one.
Corrected methylation degree
Given an observed level of methylation, measured in an in-
dividual (either in the case or in the control group) at a par-
ticular CpG within DMR or a CGI, the corrected methyla-
tion degree can be obtained. However, differently from (12),
where it can be calculated analytically by inverting the equa-
tion that describes the calibration curve, both Moskalev’s
CPR and MethylCal require a numerical procedure to per-
form the PCR-bias correction. In (15), the corrected methy-
lation degree is obtained by solving
x̂j = arg min
xj
(yobsj − β̂ j x j )2, (9)
where x̂j ∈ [0%, 100%] is the corrected methylation degree,
yobsj ∈ [0%, 100%] is the observed level of methylation at
the jth CpG, β̂ j = (β̂0 j , β̂1 j , β̂2 j , β̂3 j ) is the maximum like-
lihood solution of the CPR for the jth CpG based on ap-
parent level of methylation after PCR in the standard con-
trols and x j = (1, x1j , x2j , x3j )T. The existence of an unique
solution depends on β̂ j , but in the examples considered
Moskalev’s CPR is a strict increasing function. Thus, the
objective function (9) admits only one solution which can
be obtained by the R function optimize.
The derivation of the objective function for MethylCal’s
mixed additive regression model is slightly more compli-
cated since only few known values of the actual methyla-
tion percentage are usually tested in a calibration experi-
ment. This is a typical problem in linear mixed models when
the predictions are made for new observations, as these pre-
dictions are conditional on an unobserved level of the ran-
dom effect (31). To overcome this problem, we consider
ηi = E(AMPi |y) the posterior mean of the random-effects
AMP at the ith level. Note that i is also the predicted value
of the random-effects AMP at the same ith level of the ob-
servation xij. A cubic spline interpolation is then fitted on
the posterior means i (i = 1, . . . , l) and, by doing so, a
new value (xj) can be predicted for any value of the ac-
tual methylation percentage xj, see Supplementary Figure
S.8 for illustrative examples of the cubic spline interpola-
tion of the posterior mean of the random-effects AMP. Fi-
nally, for each CpG (j = 1, . . . , m), the PCR-bias corrected
methylation degree x̂j ∈ [0%, 100%] is the solution of
x̂j = arg min
xj
[yobsj − {E(β|y)x j + η(xj ) + Cj }]2, (10)
where E(β|y) is the posterior mean of the fixed effects, (xj)
is the cubic spline predicted value of the random-effects
AMP at the new observation xj, Cj = 0, Cj = E(CpG j |y),
Cj = E(μ j |y) and Cj = E(CpG j |y)+E(CpG∗j |y)xj for
model M1, M2, M3 and M4, respectively. In (10) the
existence of an unique solution depends on the combined
effect of E(β|y), (xj) and Cj, but in the examples analysed,
MethylCal’s calibration curve is strictly increasing, allowing
for an unique solution. For each CpG, the numerical value
of x̂j is then obtained by using the R function optimize,
specifying (10) as the objective function.
RESULTS
The assays presented in Table 1 were analysed using Methyl-
Cal and Moskalev’s CPR. First, for each specific assay, we
derived the calibration curves using five standard controls
with known methylation percentages. Second, we checked
the goodness of fit of the calibration curves obtained by
MethylCal and compared the results with those obtained by
Moskalev’s CPR. Third, we corrected the observed methy-
lation degree based on the estimated calibration curves in
two specific target regions (KCNQ1OT1 and H19/IGF2)
important for their BWS clinical diagnostic value and in
three target genes that have been associated with suscepti-
bility to celiac disease. The three steps are detailed below.
Derivation of the calibration curves
We obtained specific calibration curve for each assay us-
ing the proposed method and compared the results with
Moskalev’s CPR. Figure 1 shows the level of methylation of
two assays KCNQ1OT1 (top panels) and H19/IGF2 (bot-
tom panels) predicted by Moskalev’s CPR, whereas Fig-
ure 2 shows the results obtained by MethylCal. Moskalev’s
CPR is an over-parameterized model: when the actual
methylation percentages (AMP) at 0%, 25%, 50%, 75% and
100% are used in the calibration experiment, the number
of estimated parameters for each CpG (four for the regres-
sion coefficients and one for the residual variance) equals
the number of observations, leaving no degrees of freedom.
Thus, the 95% prediction confidence interval is extremely
wide, see Figure 1B–E, with a large uncertainty regarding
the estimated model. In contrast, Figure 2B–E highlight
the parsimony of MethylCal. Using all n = l × m obser-














 user on 27 N
ovem
ber 2019
e81 Nucleic Acids Research, 2019, Vol. 47, No. 14 PAGE 6 OF 14
Figure 1. Methylation level of two independent assays KCNQ1OT1 (top panels) and H19/IGF2 (bottom panels) calibrated by Moskalev’s cubic polynomial
regression (CPR). (A–D) The apparent level of methylation observed after amplification (y-axis) is plotted as a function of the actual methylation percentage
(AMP) (x-axis). Circles depict the apparent level of methylation after PCR for each CpG at different AMPs, whereas the red dotted lines show Moskalev’s
CPR for each CpG. The grey dash-dotted line represents an unbiased plot. (B–E) The apparent level of methylation observed after amplification (y-axis) is
plotted (circles) as a function of the CpGs in the DMR (x-axis), stratified by AMP (top figure box and the grey dot-dashed line). For each stratum, the red
dotted line shows the level of methylation predicted by Moskalev’s CPR, whereas the red dot-dashed lines depict the 95% prediction confidence interval.
(C–F) The result of PCR-bias correction by using Moskalev’s CPR. The corrected methylation degree (y-axis) is plotted as a function of the AMP (x-axis).
The grey dash-dotted line represents an unbiased corrected plot.
higher degrees of freedom, the 95% prediction credible in-
terval are much smaller than Moskalev’s CPR. Moreover,
using MethylCal, the predicted level of methylation are very
close to the apparent level of methylation after PCR. This is
evident by looking at Figure 2 A-D, where model M4 and
M3 were selected by the DIC for the assay KCNQ1OT1 and
H19/IGF2. In both assays, MethylCal interpolates the ap-
parent level of methylation observed after amplification re-
markably well despite the fact that the data show a more
complex pattern than previously reported hyperbolic (12)
or cubic polynomial (15) shape when the apparent level of
methylation after PCR is plotted as a function of the ac-
tual methylation percentage. In contrast, in Figure 1A–D,
Moskalev’s CPR is not able to interpolate the data with
the same precision, in particular for the inner values of the
AMPs (25%, 50%, 75%). Finally, Figures 1C–F and 2C–F
show the impact of the interpolation on the PCR-bias cor-
rection. For each CpG-AMP combination, (9) and (10) are
used to correct the apparent level of methylation after PCR.
If the correction is perfect, the corrected methylation de-
grees will coincide with the AMPs used in the calibration
experiment. Overall, MethylCal’s correction is more precise
than Moskalev’s adjustment due to its ability to interpolate
adequately the apparent level of methylation after PCR at
different AMPs.
By visual inspection of MethylCal’s results presented in
Figure 2F, some measurements seem less well calibrated at
75% actual methylation. A closer look at Figure 2E reveals
that the apparent level of methylation after PCR for CpG 12
is outside the posterior predictive interval [l, u] for outliers
detection with l = Q1 − 1.5IQR and u = Q3 + 1.5IQR with
IQR = Q3 − Q1 and Q3 and Q1 the 75th and 25th per-
centiles of the posterior predictive density. A second CpG
outside the posterior predictive interval for outliers detec-
tion is present also at 100% actual methylation although in
this case, given the shape of the PCR-bias correction curve,
the impact on the calibration is less pronounced. Under the
fitted MethylCal’s model, these observations can be either
regarded as outliers, and thus removed from the analysis, or
the data generation process, including biological and bio-
chemical factors, should be further investigated to under-
stand the possible causes of this unusual pattern. This con-
clusion highlights a further feature of MethylCal, i.e., its
ability to pinpoint specific CpG-AMP combinations as po-
tential outliers that do not fit with the bulk of the data and
need to be further checked.
The predicted level of methylation and the PCR-bias cor-
rection for the rest of the assays analysed, two CGIs (SDHC
CpG:17 and SDHC CpG:27) located on SDHC gene














 user on 27 N
ovem
ber 2019
PAGE 7 OF 14 Nucleic Acids Research, 2019, Vol. 47, No. 14 e81
Figure 2. Methylation level of two independent assays KCNQ1OT1 (top panels) and H19/IGF2 (bottom panels) calibrated by MethylCal with model
M4 and M3 selected by the DIC, respectively. (A–D) The apparent level of methylation observed after amplification (y-axis) is plotted as a function of
the actual methylation percentage (AMP) (x-axis). Circles depict the apparent level of methylation after PCR for each CpG at different AMPs, whereas
the red dotted lines show MethylCal’s predicted level of methylation for each CpG. Black dots highlight potential outliers. The grey dash-dotted line
represents an unbiased plot. (B–E) The apparent level of methylation observed after amplification (y-axis) is plotted (circles) as a function of the CpGs in
the DMR (x-axis), stratified by AMP (top figure box and the grey dot-dashed line). For each stratum, the red dotted line shows the level of methylation
predicted by MethylCal, whereas the red dot-dashed lines depict the 95% prediction credible interval. (C–F) The result of PCR-bias correction obtained by
using MethylCal. The corrected methylation degree (y-axis) is plotted as a function of the AMP (x-axis). The grey dash-dotted line represents a unbiased
corrected plot.
MEST and MEG3) are shown in Supplementary Figures
S.4 and S.5 for Moskalev’s CPR and in Supplementary
Figures S.6 and S.7 for MethylCal. The results are simi-
lar to those presented in Figures 1 and 2 with larger pre-
diction credible intervals, less accurate predicted level of
methylation and worse corrected methylation degree when
Moskalev’s CPR is used. These conclusions are similar
across different assays, including the previously reported cu-
bic polynomial data shape as shown for the PLAGL1 assay
in Supplementary Figures S.4G and S.6G.
Finally, by visual inspection of the data, three CpGs (21–
23) were removed from the PLAGL1 assay since their pat-
tern was extremely different from other observations in the
same assay. While Moskalev’s CPR cannot impute missing
CpGs, MethylCal is able to impute them, see Supplemen-
tary Figure S.6H, based on the fixed-effects terms (which
are common to all CpGs) and the posterior mean of the
random-effects AMP, see Supplementary Figure S.8C.
Goodness of fit
MethylCal’s superior performance compared to Moskalev’s
CPR is also apparent when the ‘in-sample’ and ‘out-of-
sample’ goodness-of-fit measures are considered. Table 2
shows the predictive performance for two assays tested,
KCNQ1OT1 and H19/IGF2. The best MethylCal’s model
selected by the DIC performs better than Moskalev’s CPR
when the Residual Sum of Squares (RSS) is considered.
These results demonstrate that, although Moskalev’s CPR
is an over-parameterised model that should attain better ‘in-
sample’ prediction, it is not suitable for calibration when
the data do not show previously reported hyperbolic or cu-
bic polynomial data shapes. The same conclusions can be
drawn for the other assays presented in Supplementary Ta-
ble S.1. MethylCal shows better predictive performance in
all assays tested and only marginally worst for the GRB10
assay. MethylCal performs better also in the PLAGL1 assay
which is the most favourable case for Moskalev’s CPR given
the cubic polynomial shape of the data.
Our comparisons also consider the ‘out-of-sample’ pre-
diction and three possible scenarios are examined. In the
first one, the cross-validation is performed by removing a
data point that corresponds to a specific CpG-AMP com-
bination. In the second scenario, each CpG is excluded one-
at-a-time, while in the last scenario each AMP is removed
separately in the cross-validation. Since Moskalev’s method
cannot predict the AMPs of the CpGs that have been re-
moved, in the second scenario the ‘out-of-sample’ predic-
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Table 2. Goodness-of-fit performance of MethylCal and Moskalev’s cubic polynomial regression (CPR) on two independent assays KCNQ1OT1 and
H19/IGF2
Moskalev MethylCal
M1 M2 M3 M4
DIC – 173.55 172.46 167.87 164.68
RSS 474.48 33.19 27.31 27.67 17.09
KCNQ1OT1 CpGs & AMPs MSEP 450.86 42.85
CV-index –1021.74 –0.15
CpGs MSEP 30.60 2.20
CV-index –12.88 0.00
AMPs MSEP 7664.54 7607.29
DIC – 179.06 180.42 178.21 180.82
RSS 369.68 56.49 52.01 51.35 37.56
H19/IGF2 CpGs & AMPs MSEP 497.94 1.12
CV-index –443.57 0.00
CpGs MSEP 35.01 5.34
CV-index –5.25 0.05
AMPs MSEP 5975.23 5799.02
For each MethylCal’s model the Deviance Information Criterion (DIC) is calculated and for MethylCal’s models and Moskalev’s CPR also the Residual
Sum of Squares (RSS). The Mean Squared Error of Prediction (MSEP) and the CV-index are evaluated for the best MethylCal’s model (based on the DIC)
and for Moskalev’s CPR when the leave-one-out cross-validation is performed across (i) CpGs and actual methylation percentages (AMPs); (ii) CpGs; (iii)
AMPs. For each predictive measure, the best result is highlighted in bold.
of the two flanking CpGs, each of them weighted by the dis-
tance (in bp) between the excluded CpG and each flanking
CpG.
In all assays tested, the Mean Squared Error of Prediction
(MSEP) of the best identified MethylCal’s model is lower
than Moskalev’s CPR by several orders of magnitude when
the cross-validation is performed across CpG-AMP com-
binations or across CpGs, see Table 2 and Supplementary
Table S.1. When the cross-validation is performed across
AMPs the difference between MethylCal and Moskalev’s
CPR is less evident. Since in this scenario an AMP has been
removed from all CpGs, MethylCal cannot borrow infor-
mation about the excluded AMP across CpGs. Nonethe-
less, MethylCal has lower MSEP than Moskalev’s method
across all assays analysed, with a gain ranging between 1%
and 5%. The improvement for the GRB10 assay (∼43%) is
particularly high since in this case the exclusion of a cali-
bration sample does not hurt the estimation of the random-
effects AMPi, see Supplementary Figure S.8E. Taken to-
gether, these results suggest that MethylCal should be also
preferred when the number of calibration samples is re-
duced from five to four.
We also evaluate MethylCal’s performance by using
the CV-index. Interestingly, the CV-index for Moskalev’s
CPR is always negative when a CpG-AMP combina-
tion is removed in the cross-validation. Thus, a non-
parametric model that predicts the CpG-AMP combina-
tion by using the remaining observations performs better
than Moskalev’s CPR. This is also true when a CpG is
excluded in the cross-validation, but the GRB10 assay. In
contrast, when looking at the CV-index, selected the best
MethylCal’s model is always better than Moskalev’s CPR
and it has an inferior CV-index performance only in one
case (KCNQ1OT1 assay) in the prediction of the CpG-
AMP combination and another one (SDHC CpG:17) in the
CpG ‘out-of-sample’ prediction.
Finally, Supplementary Table S.2 summarizes Methyl-
Cal’s goodness-of-fit measures across all assays tested and
compares them with Moskalev’s CPR. MethylCal’s best
model selected by the DIC performs always better than
Moskalev’s CPR in the ‘in-sample’ prediction, but in a
single assay. In the ‘out-of-sample’ prediction MethylCal’s
best model is always better than Moskalev’s CPR (with
the exception of the GRB10 assay) either considering the
MSEP or the CV-index measures. Moreover, MethylCal’s
best model has a non-negative CV-index in 14 out of 16
cases.
Application in clinical diagnostic of Beckwith–Wiedemann
syndrome
BWS is caused by genetic and epigenetic abnormalities on
chr11p15.5–11p15.4 that produce an increment of IGF2
growth factor levels and/or a reduction of CDKN1C
growth suppressor protein levels. The loss of methylation of
maternal KCNQ1OT1 and the gain of methylation of ma-
ternal H19/IGF2 are the most frequent defects in BWS. In
addition, the frequency of mosaicism is high in BWS, intro-
ducing the problem of borderline cases that are difficult to
diagnose.
The observed methylation levels of 15 healthy controls
and 18 potential BWS patients were corrected using the cali-
bration curves obtained by MethylCal and Moskalev’s CPR
in the KCNQ1OT1 and H19/IGF2 assays. Patients with
an average corrected methylation level below a 3SD confi-
dence interval were considered to undergo loss of methyla-
tion and those with a level above the 3SD confidence inter-
val were considered to experience gain of methylation, see
Figures 3A–B and 4A–B for the assays KCNQ1OT1 and
H19/IGF2, respectively, using Moskalev’s CPR (left pan-
els) and MethylCal (right panels). To avoid false positives,
in clinical practice a ±3SD confidence interval is usually
chosen since it guarantees low type-I error ( =0.0027).
Moreover, the confidence interval should be large enough
to contain the control samples’ corrected methylation de-
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Figure 3. Corrected methylation degree of the KCNQ1OT1 assay using Moskalev’s cubic polynomial regression (left panels) and MethylCal (right panels)
for healthy controls (top panels) and patients potentially affected by Beckwith–Wiedemann syndrome (bottom panels). (A, B) For each healthy control
(x-axis), the boxplot depicts the range and the median of the corrected methylation degree (y-axis) across CpGs. The dashed-dotted grey lines show the
±3SD confidence interval centered around the overall mean (see main text for details). (C, D) For each patient (x-axis), the boxplot depicts the range
and the mean (circle) of the corrected methylation degree (y-axis) across CpGs while the dashed-dotted grey lines show the healthy controls’ confidence
interval. Top red triangles indicate patients classified as having undergone loss or gain of methylation if their average (across CpGs) corrected methylation
degree is outside the healthy controls’ confidence interval.
Figure 3A and B present the results of the corrected
methylation degree for the KCNQ1OT1 assay in the healthy
control group. MethylCal has a larger confidence inter-
val (28.012-86.71) compared to that obtained by using
Moskalev’s CPR (37.26–81.73). This is due to the effect
of the calibration curve estimated by Moskalev’s CPR
that shrinks the corrected methylation degrees for observed
methylation levels greater than 50%, while the opposite hap-
pens for observed methylation levels lower than 50%, see
Figure 1C. The joint effect of a larger healthy controls’
confidence interval and a more accurate calibration of the
methylation degree in the patients group permit to reclas-
sify patients B5B37 as normal methylated in contrast to
Moskalev’s CPR that classifies the same patient as having
undergone loss of methylation, see Figure 3C and D. More-
over, with MethylCal, patients B5B38 and B5C41 are well
within the healthy controls’ confidence interval (including
the range of the corrected methylation degree across CpGs)
with less uncertainty about their classification.
Figure 4C and D shows the results of a second assay,
H19/IGF2, used in the classification of patients. While both
methods detected gain of methylation in patients B5A42
and B5B38, and thus affected by BWS, patient B5B37 is
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Figure 4. Corrected methylation degree of the H19/IGF2 assay using Moskalev’s cubic polynomial regression (left panels) and MethylCal (right panels)
for healthy controls (top panels) and patients potentially affected by Beckwith–Wiedemann syndrome (bottom panels). (A, B) For each healthy control
(x-axis), the boxplot depicts the range and the median of the corrected methylation degree (y-axis) across CpGs. The dashed-dotted grey lines show the
±3SD confidence interval centered around the overall mean (see main text for details). (C, D) For each patient (x-axis), the boxplot depicts the range
and the mean (circle) of the corrected methylation degree (y-axis) across CpGs while the dashed-dotted grey lines show the healthy controls’ confidence
interval. Top red triangles indicate patients classified as having undergone loss or gain of methylation if their average (across CpGs) corrected methylation
degree is outside the healthy controls’ confidence interval. Bold fonts (x-axis) indicate patients’ classification described in the main text.
MethylCal. However, in contrast to the KCNQ1OT1 assay,
in the H19/IGF2 assay there is more uncertainty regarding
the classification: for both patients B5B37 and B5B38, the
range of the corrected methylation degree across CpGs in-
tersects the upper bound of the healthy controls’ confidence
interval, while normal-classified methylated patients B5C01
and B5C06 show the same uncertainty at the bottom of the
confidence interval.
Finally, patients’ classification depends upon the choice
of the length of the healthy controls’ confidence interval.
However, when a less conservative test is chosen ( = 0.01),
MethylCal’s results do not change. This is not true when
Moskalev’s CPR is employed as shown in Supplementary
Figure S.9. This is due to Moskalev’s less precise calibration
curve and its shrinkage effect on the corrected methylation
degrees for which a small difference in the level of signifi-
cance has a large impact on the patients’ classification.
Application in clinical diagnostic of celiac patients
We applied MethylCal in a second data set containing
human genomic control DNA measured at eight distinct
AMPs (0%, 12.5%, 25%, 37.5%, 50%, 62.5%, 87.5% and
100%) in eight NFkB-related and Toll-like receptor genes
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Figure 5. Calibrated methylation level and corrected methylation degree of the NFKBIA assay in celiac patients using Moskalev’s cubic polynomial regres-
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the same target regions of 13 controls and 17 celiac patients
at the time of diagnosis with patient data pyrosequenced
in three runs (18). In our analysis we focused on NFKBIA
gene, as well as on RELA and TNFAIP3 genes that, simi-
larly to NFKBIA, have been associated with susceptibility
to celiac disease.
Figure 5 shows the calibration curves of the NFKBIA
assay and the corrected methylation degrees in celiac pa-
tients using Moskalev’s CPR (left panels) and MethylCal
(right panels). Our method confirms its ability to automat-
ically detect outliers. For example, in Figure 5B–D, several
methylation levels in CpG 5 are detected as outliers (black
dots) since they show an apparent level of methylation at
37.5%, 50% and 62.5% actual methylation that is lower than
at 25%. Similarly, there is an outlier in CpG 3 where the ap-
parent level of methylation at 50% actual methylation is as
high as at 62.5%. Outliers were also detected between 37.5%
and 62.5% actual methylation in the RELA and TNFAIP3
assays, see Supplementary Figures S.10B–D and S.11B–D,
respectively. Rather than relying on a difficult visual inspec-
tion of the data, MethylCal identifies specific CpG-AMP
combinations that do not fit with the bulk of the data and
it accounts for them when it derives the calibration curves.
See also Supplementary Table S.3 for the comparison of the
goodness of fit between MethylCal and Moskalev’s CPR on
the NFKBIA, RELA and TNFAIP3 assays and the overall
better performance of the proposed tool.
A different estimation of the calibration curves may have
a large impact on the correction of the case/controls sam-
ples and the classification of the patients. Figure 5 E-F ex-
emplify this case where Moskalev’s CPR classifies patient
16D as normal methylated, while MethylCal, besides pa-
tient 16D, identifies patients 09D and 12D as normal methy-
lated. In particular, MethylCal estimates an average cor-
rected methylation level for patient 09D (11.34) that is more
than double the level obtained by Moskalev’s CPR (5.24).
Further investigations confirm that patient 09D is always
classified by Moskalev’s CPR as having undergone loss of
methylation irrespectively of the level of significance of the
test ( ≤ 0.10).
DISCUSSION
Bisulfite amplicon sequencing is an ideal platform for the
detection of methylation changes on multiple targets in par-
allel due to the low cost and the efficiency in the single-base
quantification (32). The main limitation of this technology
is a preferential amplification of an allele and strand in the
PCR due to methylation state (12). This effect causes inac-
curate estimation of the methylation and in silico calibration
tools have been proposed to minimize it.
In this work, we proposed a new Bayesian calibration tool
that is able to analyse jointly all CpGs within a CGI or a
DMR avoiding ‘one-at-a-time’ CpG calibration. MethylCal
has several benefits compared to existing methods (12,15),
including a better ‘out-of-sample’ prediction which is par-
ticularly important in the derivation of the corrected methy-
lation degree and the ability to detect CpG-AMP combi-
nations that should be regarded as outliers, and therefore
removed or further checked. Our approach is also very gen-
eral and it is applicable irrespectively of the locus analysed
(CGIs or DMRs), the type and degree of PCR bias to be
recovered (large towards the un-methylated allele as in the
PLAGL1 assay, small towards the methylated allele as in
SDHC CpG:17), the number of CpGs per locus (few as in
the MEST assay, many as in the PLAGL1 assay) and the
number of calibration samples.
MethylCal includes four different models, each of which
with a different random-effects combination. In the analy-
sis of BWS data, M4 is the preferred model since it allows
the specification of the correlation of the apparent level of
methylation between CpGs and the AMPs. This behaviour
is particularly evident in two assays, GRB10 and MEST,
that show higher than expected methylation levels at 0% and
25% actual methylation, an effect that gradually disappears
at higher AMPs (Supplementary Figure S.3C-E). Although
less pronounced, the opposite behaviour is present in the
assays H19/IGF2 and KCNQ1OT1 (Supplementary Figure
S.3G–I) and SDHC CpG:27 (Supplementary Figure S.2B).
This pattern cannot be explained by the expected error asso-
ciated with standard controls (5% for un-methylated DNA
and an extra 5% for fully-methylated DNA). Given that the
same calibration samples were used in all reactions and the
high conversion rate (>98%), this phenomenon might be
due to regions specific resistance to bisulfite conversion. A
possible explanation is the formation of stable secondary
structures around the CpG site that makes the region more
resistant to denaturation and subsequent conversion (33).
The application of MethylCal for the calibration of
the observed methylation levels of the KCNQ1OT1 and
H19/IGF2 assays in a real data set of possible BWS cases
shows the importance of the accurate quantification and
correction of the PCR bias to distinguish borderline cases.
We considered gain of methylation in a region when the level
of methylation is above 3SD from the average methylation
level detected in the control group and loss of methylation
when the level of methylation is below 3SD. Using Methyl-
Cal, we classified patients B5B37 as having undergone gain
of methylation in the target region H19/IGF2 in contrast to
Moskalev’s method that identified the same patient with a
loss of methylation in the target region KCNQ1OT1. In the
analysis, we applied a very conservative threshold, ±3SD
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
actual methylation percentage (AMP) (x-axis). Circles depict the apparent level of methylation after PCR for each CpG at different AMPs, whereas the red
dotted lines show MethylCal’s predicted level of methylation for each CpG. Black dots highlight potential outliers. The grey dash-dotted line represents
an unbiased plot. (C-D) The apparent level of methylation observed after amplification (y-axis) is plotted (circles) as a function of the CpGs in the DMR
(x-axis), stratified by AMP (top figure box and the grey dot-dashed line). For each stratum, the red dotted line shows the level of methylation predicted
by MethylCal, whereas the red dot-dashed lines depict the 95% prediction credible interval. (E, F) For each patient (x-axis), the boxplot depicts the range
and the mean (circle) of the corrected methylation degree (y-axis) across CpGs while the dashed-dotted grey lines show the healthy controls’ confidence
interval. Top red triangles indicate patients classified as having undergone loss or gain of methylation if their average (across CpGs) corrected methylation
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(around 0.3% of false-positive error in the diagnostic), but
MethylCal’s results do not change if the level of significance
is increased to a less restrictive 1%, demonstrating that its
corrections are less influenced by the choice of the level of
the test. Finally, the benefits of the proposed method, i.e.,
better calibrations and more reliable corrections, are also
shown in a second case/control data set related to pyrose-
quenced methylation levels in three target regions associ-
ated with susceptibility to celiac disease.
In both real data applications, the improvement in the ac-
curacy observed after calibration determines the diagnosis,
but it could also influence clinical or treatment decisions or
further actions. Moreover, the accuracy of the calibration
method is critical in disorders with mosaicism like BWS but
not exclusive, since the same problem will affect, for exam-
ple, circulating tumor DNA samples, which will have exten-
sive application in cancer diagnostic in a near future.
In conclusion, MethylCal learns the presence, location
and size of PCR bias better than existing methods and ad-
justs for it in the correction step, allowing the identification
of loss or gain of methylation in difficult cases with less un-
certainty compared to existing methods. The availability as
a user-friendly R package will also permit its routine appli-
cation in clinical diagnostic and research laboratories.
SOFTWARE
Written in R and available as an R package on https://
github.com/lb664/MethylCal.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Tümer,Z., Monk,D., Mackay,D.J., Grønskov,K., Riccio,A.,
Linglart,A. et al. (2015) Imprinting disorders: a group of congenital
disorders with overlapping patterns of molecular changes affecting
imprinted loci. Clin. Epigenet., 7, 123.
10. Mikeska,T., Bock,C., Do,H. and Dobrovic,A. (2012) DNA
methylation biomarkers in cancer: progress towards clinical
implementation. Expert Rev. Mol. Diagn., 12, 473–487.
11. Bock,C., Halbritter,F., Carmona,F.J., Tierling,S., Datlinger,P.,
Assenov,Y., Berdasco,M., Bergmann,A.K., Booher,K., Busato,F.
et al. (2016) Quantitative comparison of DNA methylation assays for
biomarker development and clinical applications. Nat. Biotechnol.,
34, 726.
12. Warnecke,P.M., Stirzaker,C., Melki,J.R., Millar,D.S., Paul,C.L. and
Clark,S.J. (1997) Detection and measurement of PCR bias in
quantitative methylation analysis of bisulphite-treated DNA. Nucleic
Acids Res., 25, 4422–4426.
13. Wojdacz,T.K., Hansen,L.L. and Dobrovic,A. (2008) A new approach
to primer design for the control of PCR bias in methylation studies.
BMC Res. Notes, 1, 54.
14. Wojdacz,T.K., Borgbo,T. and Hansen,L.L. (2009) Primer design
versus PCR bias in methylation independent PCR amplifications.
Epigenetics, 4, 231–234.
15. Moskalev,E.A., Zavgorodnij,M.G., Majorova,S.P., Vorobjev,I.A.,
Jandaghi,P., Bure,I.V. and Hoheisel,J.D. (2011) Correction of
PCR-bias in quantitative DNA methylation studies by means of cubic
polynomial regression. Nucleic Acids Res., 39, e77.
16. Fernandez-Jimenez,N., Plaza-Izurieta,L., Lopez-Euba,T.,
Jauregi-Miguel,A. and Ramon Bilbao,J. (2012) Cubic
regression-based degree of correction predicts the performance of
whole bisulfitome amplified DNA methylation analysis. Epigenetics,
7, 1349–1354.
17. Maher,E.R. and Reik,W. (2000) Beckwith–Wiedemann syndrome:
imprinting in clusters revisited. J. Clin. Invest., 105, 247–252.
18. Fernandez-Jimenez,N., Castellanos-Rubio,A., Plaza-Izurieta,L.,
Irastorza,I., Elcoroaristizabal,X., Jauregi-Miguel,A., Lopez-Euba,T.,
Tutau,C., de Pancorbo,M.M., Vitoria,J.C. et al. (2013) Coregulation
and modulation of NF	B-related genes in celiac disease: uncovered
aspects of gut mucosal inflammation. Hum. Mol. Genet., 23,
1298–1310.
19. Yu,H., Hahn,Y. and Yang,I. (2015) Reference materials for
calibration of analytical biases in quantification of DNA methylation.
PLoS One, 10, e0137006.
20. Masser,D.R., Berg,A.S. and Freeman,W.M. (2013) Focused, high
accuracy 5-methylcytosine quantitation with base resolution by
benchtop next-generation sequencing. Epigenet. Chromatin, 6, 33.
21. Spiegelhalter,D.J., Best,N.G., Carlin,B.P. and Van Der Linde,A.
(2002) Bayesian measures of model complexity and fit. J. R. Stat. Soc.
B Met., 64, 583–639.
22. Pinheiro,J.C. and Bates,D.M. (2000) Linear mixed-effects models:
basic concepts and examples. In: Mixed-effects models in S and














 user on 27 N
ovem
ber 2019
e81 Nucleic Acids Research, 2019, Vol. 47, No. 14 PAGE 14 OF 14
23. Rue,H., Martino,S. and Chopin,N. (2009) Approximate Bayesian
inference for latent Gaussian models by using integrated nested
Laplace approximations. J. R. Stat. Soc. B Met., 71, 319–392.
24. Rackham,O.J., Langley,S.R., Oates,T., Vradi,E., Srivastava,P.K.,
Behmoaras,J., Dellaportas,P., Bottolo,L. and Petretto,E. (2017) A
Bayesian approach for analysis of whole-genome bisulfite sequencing
data identifies disease-associated changes in DNA methylation.
Genetics, 205, 1443–1458.
25. Rue,H. and Held,L. (2005) Gaussian Markov Random Fields: Theory
and Applications, CRC Press.
26. Zhang,W., Spector,T.D., Deloukas,P., Bell,J.T. and Engelhardt,B.E.
(2015) Predicting genome-wide DNA methylation using methylation
marks, genomic position, and DNA regulatory elements. Genome
Biol., 16, 14.
27. Tierney,L. and Kadane,J.B. (1986) Accurate approximations for
posterior moments and marginal densities. J. Am. Stat. Assoc., 81,
82–86.
28. Rue,H. and Martino,S. (2007) Approximate Bayesian inference for
hierarchical Gaussian Markov random field models. J. Stat. Plan
Infer., 137, 3177–3192.
29. Sundberg,R. (1999) Multivariate calibration–direct and indirect
regression methodology. Scand. J. Stat., 26, 161–207.
30. Stone,M. and Brooks,R.J. (1990) Continuum regression:
cross-validated sequentially constructed prediction embracing
ordinary least squares, partial least squares and principal components
regression. J. R. Stat. Soc. B Met., 52, 237–269.
31. Welham,S., Cullis,B., Gogel,B., Gilmour,A. and Thompson,R. (2004)
Prediction in linear mixed models. Aust. NZ J. Stat., 46, 325–347.
32. Grunau,C., Clark,S. and Rosenthal,A. (2001) Bisulfite genomic
sequencing: systematic investigation of critical experimental
parameters. Nucleic Acids Res., 29, e65.
33. Warnecke,P.M., Stirzaker,C., Song,J., Grunau,C., Melki,J.R. and
Clark,S.J. (2002) Identification and resolution of artifacts in bisulfite














 user on 27 N
ovem
ber 2019
